U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C32H32O13S
Molecular Weight 656.654
Optical Activity UNSPECIFIED
Defined Stereocenters 10 / 10
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TENIPOSIDE

SMILES

[H][C@]12COC(=O)[C@]1([H])[C@H](C3=CC(OC)=C(O)C(OC)=C3)C4=C(C=C5OCOC5=C4)[C@H]2O[C@]6([H])O[C@]7([H])CO[C@H](O[C@@]7([H])[C@H](O)[C@H]6O)C8=CC=CS8

InChI

InChIKey=NRUKOCRGYNPUPR-QBPJDGROSA-N
InChI=1S/C32H32O13S/c1-37-19-6-13(7-20(38-2)25(19)33)23-14-8-17-18(42-12-41-17)9-15(14)28(16-10-39-30(36)24(16)23)44-32-27(35)26(34)29-21(43-32)11-40-31(45-29)22-4-3-5-46-22/h3-9,16,21,23-24,26-29,31-35H,10-12H2,1-2H3/t16-,21+,23+,24-,26+,27+,28+,29+,31+,32-/m0/s1

HIDE SMILES / InChI

Description

Teniposide is an inhibitor of topoisomerase II with anti-cancer activity. The drug was approved by FDA under the name Vumon for the treatment of children with acute lymphoblastic leukemia.

CNS Activity

CNS Non-penetrant
1014
Curator's Comment: Teniposide appears not to cross the blood brain barrier, although in a study in patients with brain tumors, CSF levels of teniposide were higher than CSF levels reported in other studies of patients who did not have brain tumors.

Originator

Approval Year

1992
115
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
VUMON

Approved Use

Teniposide Injection, in combination with other approved anticancer agents, is indicated for induction therapy in patients with refractory childhood acute lymphoblastic leukemia.

Launch Date

1992
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
7083.9 ng/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/4017164
30 mg/m² single, intravenous
dose: 30 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
TENIPOSIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1937.3 μg × min/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/4017164
30 mg/m² single, intravenous
dose: 30 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
TENIPOSIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
20.3 h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/4017164
30 mg/m² single, intravenous
dose: 30 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
TENIPOSIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
1%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020119s010s011lbl.pdf
TENIPOSIDE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
60 mg/m2 5 times / 3 weeks multiple, intravenous
Dose: 60 mg/m2, 5 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 60 mg/m2, 5 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305702
unhealthy, 64 years (range: 46–83 years)
n = 41
Health Status: unhealthy
Condition: small cell lung carcinoma
Age Group: 64 years (range: 46–83 years)
Sex: M+F
Population Size: 41
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305702
Other AEs: Infection, Neutropenia...
Other AEs:
Infection (grade 5, 1 patient)
Neutropenia (grade 4, 15 patients)
Neutropenia (grade 3, 8 patients)
Neutropenia (grade 1-2, 6 patients)
Anemia (grade 3, 4 patients)
Anemia (grade 1-2, 20 patients)
Thrombocytopenia (grade 3, 3 patients)
Thrombocytopenia (grade 1-2, 8 patients)
Infection (grade 3, 4 patients)
Infection (grade 1-2, 1 patient)
Fever (grade 1-2, 2 patients)
Nausea (grade 3, 1 patient)
Nausea (grade 1-2, 19 patients)
Vomiting (grade 3, 1 patient)
Vomiting (grade 1-2, 8 patients)
Hyponatremia (grade 4, 1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305702
165 mg/m2 2 times / week multiple, intravenous
Recommended
Dose: 165 mg/m2, 2 times / week
Route: intravenous
Route: multiple
Dose: 165 mg/m2, 2 times / week
Co-administed with::
cytarabine(300 mg/m2, twice weekly for 8 to 9 doses)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020119s013lbl.pdf
unhealthy, children
Health Status: unhealthy
Condition: acute lymphoblastic leukemia
Age Group: children
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020119s013lbl.pdf
Other AEs: Myelosuppression, Anaphylactic reaction...
Other AEs:
Myelosuppression (severe)
Anaphylactic reaction
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020119s013lbl.pdf
AEs

AEs

AESignificanceDosePopulation
Infection grade 1-2, 1 patient
60 mg/m2 5 times / 3 weeks multiple, intravenous
Dose: 60 mg/m2, 5 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 60 mg/m2, 5 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305702
unhealthy, 64 years (range: 46–83 years)
n = 41
Health Status: unhealthy
Condition: small cell lung carcinoma
Age Group: 64 years (range: 46–83 years)
Sex: M+F
Population Size: 41
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305702
Nausea grade 1-2, 19 patients
60 mg/m2 5 times / 3 weeks multiple, intravenous
Dose: 60 mg/m2, 5 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 60 mg/m2, 5 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305702
unhealthy, 64 years (range: 46–83 years)
n = 41
Health Status: unhealthy
Condition: small cell lung carcinoma
Age Group: 64 years (range: 46–83 years)
Sex: M+F
Population Size: 41
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305702
Fever grade 1-2, 2 patients
60 mg/m2 5 times / 3 weeks multiple, intravenous
Dose: 60 mg/m2, 5 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 60 mg/m2, 5 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305702
unhealthy, 64 years (range: 46–83 years)
n = 41
Health Status: unhealthy
Condition: small cell lung carcinoma
Age Group: 64 years (range: 46–83 years)
Sex: M+F
Population Size: 41
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305702
Anemia grade 1-2, 20 patients
60 mg/m2 5 times / 3 weeks multiple, intravenous
Dose: 60 mg/m2, 5 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 60 mg/m2, 5 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305702
unhealthy, 64 years (range: 46–83 years)
n = 41
Health Status: unhealthy
Condition: small cell lung carcinoma
Age Group: 64 years (range: 46–83 years)
Sex: M+F
Population Size: 41
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305702
Neutropenia grade 1-2, 6 patients
60 mg/m2 5 times / 3 weeks multiple, intravenous
Dose: 60 mg/m2, 5 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 60 mg/m2, 5 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305702
unhealthy, 64 years (range: 46–83 years)
n = 41
Health Status: unhealthy
Condition: small cell lung carcinoma
Age Group: 64 years (range: 46–83 years)
Sex: M+F
Population Size: 41
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305702
Thrombocytopenia grade 1-2, 8 patients
60 mg/m2 5 times / 3 weeks multiple, intravenous
Dose: 60 mg/m2, 5 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 60 mg/m2, 5 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305702
unhealthy, 64 years (range: 46–83 years)
n = 41
Health Status: unhealthy
Condition: small cell lung carcinoma
Age Group: 64 years (range: 46–83 years)
Sex: M+F
Population Size: 41
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305702
Vomiting grade 1-2, 8 patients
60 mg/m2 5 times / 3 weeks multiple, intravenous
Dose: 60 mg/m2, 5 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 60 mg/m2, 5 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305702
unhealthy, 64 years (range: 46–83 years)
n = 41
Health Status: unhealthy
Condition: small cell lung carcinoma
Age Group: 64 years (range: 46–83 years)
Sex: M+F
Population Size: 41
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305702
Nausea grade 3, 1 patient
60 mg/m2 5 times / 3 weeks multiple, intravenous
Dose: 60 mg/m2, 5 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 60 mg/m2, 5 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305702
unhealthy, 64 years (range: 46–83 years)
n = 41
Health Status: unhealthy
Condition: small cell lung carcinoma
Age Group: 64 years (range: 46–83 years)
Sex: M+F
Population Size: 41
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305702
Vomiting grade 3, 1 patient
60 mg/m2 5 times / 3 weeks multiple, intravenous
Dose: 60 mg/m2, 5 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 60 mg/m2, 5 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305702
unhealthy, 64 years (range: 46–83 years)
n = 41
Health Status: unhealthy
Condition: small cell lung carcinoma
Age Group: 64 years (range: 46–83 years)
Sex: M+F
Population Size: 41
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305702
Thrombocytopenia grade 3, 3 patients
60 mg/m2 5 times / 3 weeks multiple, intravenous
Dose: 60 mg/m2, 5 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 60 mg/m2, 5 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305702
unhealthy, 64 years (range: 46–83 years)
n = 41
Health Status: unhealthy
Condition: small cell lung carcinoma
Age Group: 64 years (range: 46–83 years)
Sex: M+F
Population Size: 41
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305702
Anemia grade 3, 4 patients
60 mg/m2 5 times / 3 weeks multiple, intravenous
Dose: 60 mg/m2, 5 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 60 mg/m2, 5 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305702
unhealthy, 64 years (range: 46–83 years)
n = 41
Health Status: unhealthy
Condition: small cell lung carcinoma
Age Group: 64 years (range: 46–83 years)
Sex: M+F
Population Size: 41
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305702
Infection grade 3, 4 patients
60 mg/m2 5 times / 3 weeks multiple, intravenous
Dose: 60 mg/m2, 5 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 60 mg/m2, 5 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305702
unhealthy, 64 years (range: 46–83 years)
n = 41
Health Status: unhealthy
Condition: small cell lung carcinoma
Age Group: 64 years (range: 46–83 years)
Sex: M+F
Population Size: 41
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305702
Neutropenia grade 3, 8 patients
60 mg/m2 5 times / 3 weeks multiple, intravenous
Dose: 60 mg/m2, 5 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 60 mg/m2, 5 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305702
unhealthy, 64 years (range: 46–83 years)
n = 41
Health Status: unhealthy
Condition: small cell lung carcinoma
Age Group: 64 years (range: 46–83 years)
Sex: M+F
Population Size: 41
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305702
Hyponatremia grade 4, 1 patient
60 mg/m2 5 times / 3 weeks multiple, intravenous
Dose: 60 mg/m2, 5 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 60 mg/m2, 5 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305702
unhealthy, 64 years (range: 46–83 years)
n = 41
Health Status: unhealthy
Condition: small cell lung carcinoma
Age Group: 64 years (range: 46–83 years)
Sex: M+F
Population Size: 41
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305702
Neutropenia grade 4, 15 patients
60 mg/m2 5 times / 3 weeks multiple, intravenous
Dose: 60 mg/m2, 5 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 60 mg/m2, 5 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305702
unhealthy, 64 years (range: 46–83 years)
n = 41
Health Status: unhealthy
Condition: small cell lung carcinoma
Age Group: 64 years (range: 46–83 years)
Sex: M+F
Population Size: 41
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305702
Infection grade 5, 1 patient
60 mg/m2 5 times / 3 weeks multiple, intravenous
Dose: 60 mg/m2, 5 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 60 mg/m2, 5 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305702
unhealthy, 64 years (range: 46–83 years)
n = 41
Health Status: unhealthy
Condition: small cell lung carcinoma
Age Group: 64 years (range: 46–83 years)
Sex: M+F
Population Size: 41
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305702
Anaphylactic reaction
165 mg/m2 2 times / week multiple, intravenous
Recommended
Dose: 165 mg/m2, 2 times / week
Route: intravenous
Route: multiple
Dose: 165 mg/m2, 2 times / week
Co-administed with::
cytarabine(300 mg/m2, twice weekly for 8 to 9 doses)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020119s013lbl.pdf
unhealthy, children
Health Status: unhealthy
Condition: acute lymphoblastic leukemia
Age Group: children
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020119s013lbl.pdf
Myelosuppression severe
165 mg/m2 2 times / week multiple, intravenous
Recommended
Dose: 165 mg/m2, 2 times / week
Route: intravenous
Route: multiple
Dose: 165 mg/m2, 2 times / week
Co-administed with::
cytarabine(300 mg/m2, twice weekly for 8 to 9 doses)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020119s013lbl.pdf
unhealthy, children
Health Status: unhealthy
Condition: acute lymphoblastic leukemia
Age Group: children
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020119s013lbl.pdf
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
substrate
1737

inhibitor
1587
inhibitor
1767

OverviewOther

Other InhibitorOther SubstrateOther Inducer
P-gp
1537

MRP3
50
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP3A4
1925
 yes [IC50 64 uM]
likely (co-administration study)
Comment: see http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Teniposide_monograph_1July2014.pdf#page=4 for list of interactions
CYP2C9
1819
 yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP3A4
1737
 major
likely (co-administration study)
Comment: see http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Teniposide_monograph_1July2014.pdf#page=4 for list of interactions
Page: 4.0
MRP3
50
 yes
P-gp
1537
 yes
Sourcing

Sourcing

Vendor/AggregatorIDURL
001 Chemical
DY547001
https://www.001chemical.com/chem/29767-20-2
3B Scientific (Wuhan) Corp
3B2-1312
http://www.3bsc.com/index/pro_info.php?id=55028
AA Blocks
AA00I5FJ
https://www.aablocks.com/goods/Goods/detail?id=AA00I5FJ
AHH Chemical co.,ltd
MT-00056
http://www.ahhchemical.com/product/MT-00056.html
AK Scientific, Inc. (AKSCI)
69655
http://www.aksci.com/item_detail.php?cat=69655
Aaron Chemicals
AR00I67B
http://www.aaronchem.com/29767-20-2
AbMole Bioscience
M3313
http://www.abmole.com/products/teniposide.html
Acadechem
ACDC-030273
http://acadechemical.com/product/1986
Achemo Scientific Limited
AC-63286
http://www.achemo.com/search/?Keyword= 29767-20-2
Achemtek
0104-019659
http://www.achemtek.com/29767-20-2
Alfa Chemistry
AP29767202
https://reagents.alfa-chemistry.com/product/teniposide-cas-29767-20-2-9410.html
Ambeed
A102576
https://www.ambeed.com/products/29767-20-2.html
Ambinter
Amb16193060
http://www.ambinter.com/reference/16193060
Ambinter
Amb22492542
http://www.ambinter.com/reference/22492542
Angel Pharmatech
AG201104
http://www.angelpharmatech.com/29767-20-2.html
ApexBio Technology
A8532
http://www.apexbt.com/teniposide.html
Ark Pharm
AK326113
http://www.arkpharminc.com/products/29767-20-2.html
Aurora Fine Chemicals LLC
A24.079.230
http://online.aurorafinechemicals.com/info?ID=A24.079.230
Aurum Pharmatech LLC
W-5144
http://www.Aurumpharmatech.com/Product/ProductDetails/W_5144
AvaChem Scientific
2712
http://www.avachem.com/productSearch.asp?2712
Avantor Inc
TCT3109-100MG
https://us.vwr.com/store/product/16815322/teniposide-98-0-by-hplc
Avantor Inc
TCT3109-20MG
https://us.vwr.com/store/product/16815322/teniposide-98-0-by-hplc
BLD Pharm
BD152568
http://www.bldpharm.com/products/29767-20-2.html
BioChemPartner
BCP08940
http://www.biochempartner.com/29767-20-2-BCP08940
BioCrick
BCC3864
http://www.biocrick.com/Teniposide-BCC3864.html
BioCyc
CPD-16755
https://biocyc.org/compound?orgid=META&id=CPD-16755
BioSynth
J-017623
https://www.biosynth.com/en/products/all-products/products/J-017623.html
Boerchem
BC218913
http://www.boerchem.com/?product_36850.html
CSNpharm
CSN12049
https://www.csnpharm.com/products/teniposide.html
Chem Scene
CS-1366
http://www.chemscene.com/29767-20-2.html
ChemMol
30108888
http://www.chemmol.com/chemmol/30108888.html
ChemMol
44005778
http://www.chemmol.com/chemmol/44005778.html
ChemMol
49409320
http://www.chemmol.com/chemmol/49409320.html
ChemMol
99059300
http://www.chemmol.com/chemmol/99059300.html
Chemspace
CSSB00116206870
https://chem-space.com/CSSB00116206870
Chemspace
CSSS02495358825
https://chem-space.com/CSSS02495358825
Clearsynth
CS-T-61638
https://www.clearsynth.com/en/CST61638.html
DC Chemicals
DCAPI1145
http://www.dcchemicals.com//product_show-Teniposide_Vumon_.html
Finetech
FT-0601556
http://www.finetechnology-ind.com/prod/detail/pub/29767-20-2.html
Glentham Life Sciences
GP2668
http://www.glentham.com/products/product/GP2668/
Hairui
HR126555
http://www.hairuichem.com/en/product/29767-20-2.html
Lab Network
LN01327320
https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01327320
MedChem Express
HY-13761
https://www.medchemexpress.com/Teniposide.html
MolPort
MolPort-009-684-460
https://www.molport.com/shop/molecule-link/MolPort-009-684-460
Molcore
MC547001
https://www.molcore.com/product/29767-20-2
MuseChem
A000506
https://www.musechem.com/product/A000506.html
OChem
5251
http://www.ocheminc.com/index.php?act=psearch&pid=767T202
Smolecule
S548645
http://www.smolecule.com/products/s548645
Smolecule
S752266
https://www.smolecule.com/products/s752266
Synchem UG and Co KG
67400
http://www.synchem.de/chemical_Teniposide.html
TCI (Tokyo Chemical Industry)
T3109
http://www.tcichemicals.com/eshop/en/us/commodity/T3109/index.html
THE BioTek
bt-288052
https://www.thebiotek.com/product/inhibitors/bt-288052
VladaChem
VL277300-1G
https://www.vladachem.com/product.php?products=29767-20-2
Yuhao Chemical
LX2053
http://www.chemyuhao.com/29767-20-2.html
abcr GmbH
AB452154
http://www.abcr.com/shop/en/AB452154
abcr GmbH
AB508784
http://www.abcr.com/shop/en/AB508784
eNovation Chemicals
D480432
http://www.enovationchem.com/productDetails.asp?productID=D480432
PubMed

PubMed

TitleDatePubMed
Application of pharmacokinetic modelling to the routine therapeutic drug monitoring of anticancer drugs.
2002 Aug
[Teniposide and cisplatin compared with etoposide and cisplatin for treatment of small cell lung cancer].
2002 Dec
[Chemosensitivity testing of oral and maxillofacial cancer with biopsy specimens].
2002 Nov
Characterization of the drug resistance and transport properties of multidrug resistance protein 6 (MRP6, ABCC6).
2002 Nov 1
The role of caspases 9 and 9-short (9S) in death ligand- and drug-induced apoptosis in human astrocytoma cells.
2002 Oct 15
Platinum drugs in the treatment of non-small-cell lung cancer.
2002 Oct 7
Study of either ifosfamide or teniposide compared to a standard chemotherapy for extensive disease small cell lung cancer: an Eastern Cooperative Oncology Group randomized study (E1588).
2002 Sep
Successful paternity with microassisted fertilization after total body irradiation-based conditioning for autologous bone marrow transplantation.
2003
Taxanes in the treatment of advanced (stage III and IV) non-small cell lung cancer (NSCLC): recent developments.
2003
Disseminated neuroblastoma in children older than one year at diagnosis: comparable results with three consecutive high-dose protocols adopted by the Italian Co-Operative Group for Neuroblastoma.
2003 Apr 15
Substituted benzo[i]phenanthridines as mammalian topoisomerase-targeting agents.
2003 Apr 17
Inhibition of DNA topoisomerases I and II, and growth inhibition of human cancer cell lines by a marine microalgal polysaccharide.
2003 Aug 1
Effect of Aplidin in acute lymphoblastic leukaemia cells.
2003 Aug 18
[Evaluation of efficacy of treatment for 30 children with neuroblastoma].
2003 Dec
Carboplatin and teniposide as third-line chemotherapy in patients with recurrent oligodendroglioma or oligoastrocytoma: a phase II study.
2003 Dec
High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962.
2003 Dec 15
Survival with dacarbazine and fotemustine in newly diagnosed glioblastoma multiforme.
2003 Feb 24
Recent advances in traditional plant drugs and orchids.
2003 Jan
Dental abnormalities in children after chemotherapy treatment for acute lymphoid leukemia.
2003 Jan
Feasibility of combination chemotherapy with cisplatin and etoposide for haemodialysis patients with lung cancer.
2003 Jan 13
Interactions between antiepileptic and chemotherapeutic drugs.
2003 Jul
DNA sequence specificity for topoisomerase II poisoning by the quinoxaline anticancer drugs XK469 and CQS.
2003 Jun
Cell proliferation is related to in vitro drug resistance in childhood acute leukaemia.
2003 Mar 10
Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein.
2003 Mar 15
Regulatory approvals of pediatric oncology drugs: previous experience and new initiatives.
2003 Mar 15
[Treatment of malignant non-Hodgkin's lymphoma. Economic impact of rituximab (Mabthera) versus conventional chemotherapy].
2003 May
Enhanced production of podophyllotoxin by Podophyllum hexandrum using in situ cell retention bioreactor.
2003 May-Jun
[Chemosensitivity testing of oral squamous cell carcinomas with teniposide].
2003 Nov
Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia.
2003 Nov 17
P-glycoprotein and multidrug resistance-associated protein mediate specific patterns of multidrug resistance in malignant glioma cell lines, but not in primary glioma cells.
2003 Oct
Application of the CFU-GM assay to predict acute drug-induced neutropenia: an international blind trial to validate a prediction model for the maximum tolerated dose (MTD) of myelosuppressive xenobiotics.
2003 Oct
Neuro-Oncology Working Group 01 trial of nimustine plus teniposide versus nimustine plus cytarabine chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma.
2003 Sep 1
Extraocular retinoblastoma: a 13-year experience.
2003 Sep 15
Chemotherapy induced gastrointestinal toxicity in rats: involvement of mitochondrial DNA, gastrointestinal permeability and cyclooxygenase -2.
2003 Sep-Dec
Reduced expression of p27 is a novel mechanism of docetaxel resistance in breast cancer cells.
2004
Vincristine, cisplatin, teniposide, and cyclophosphamide combination in the treatment of recurrent or metastatic adrenocortical cancer.
2004
[Survivin antisense oligonucleotide induces lymphoma cells apoptosis and sensitizes the cells to chemotherapy].
2004 Apr
Overexpression of a dominant-negative mutant Ubc9 is associated with increased sensitivity to anticancer drugs.
2004 Apr 15
Cognitive status and quality of life after treatment for primary CNS lymphoma.
2004 Feb 24
[Significance of C-reaction protein for differential diagnosis of fever after chemotherapy on children with acute lymphoblastic leukemia].
2004 Jul
Bone marrow transplantation for therapy-related acute myeloid leukemia in congenital retinoblastoma associated with 13q deletion syndrome.
2004 Jul
Quantification of etoposide and etoposide phosphate in human plasma by micellar electrokinetic chromatography and near-field thermal lens detection.
2004 Jul 1
[Primary central nervous system lymphoma: a report of 28 patients].
2004 Jun
Regulation of DNaseY activity by actinin-alpha4 during apoptosis.
2004 Jun
Long-term efficacy of the CHVmP/BV regimen used for aggressive non-Hodgkin's lymphoma in three randomised EORTC trials.
2004 Mar
[Chemotherapy with higher or lower dose of teniposide combined with cisplatin and pingyangmycin for oral squamous cell carcinoma].
2004 May
Biotechnological aspects of the production of the anticancer drug podophyllotoxin.
2004 Oct
Kinetics and regulation of cytochrome P450-mediated etoposide metabolism.
2004 Sep
Poly(N-vinylpyrrolidone)-block-poly(D,L-lactide) as a new polymeric solubilizer for hydrophobic anticancer drugs: in vitro and in vivo evaluation.
2004 Sep 14
Podophyllotoxin: distribution, sources, applications and new cytotoxic derivatives.
2004 Sep 15
Patents

Patents

JP2005507376A
6
JP2005519871A
28
JP2005520795A
24
JP2006528196A
42
JP2007506647A
5
JP2008519861A
32
JP2009513567A
65
JP2010506837A
76
JP2011522802A
30
JP4776843B2
17
JP4787165B2
101

Sample Use Guides

In Vivo Use Guide
Teniposide Injection must be diluted with either 5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP, to give final teniposide concentrations of 0.1 mg/mL, 0.2 mg/mL, 0.4 mg/mL, or 1.0 mg/mL. It is recommended that the teniposide solution be administered over at least a 30- to 60-minute period.
Route of Administration: Intravenous
In Vitro Use Guide
Sources: www.ncbi.nlm.nih.gov/pubmed/3469013
Human leukemic cell line were treated with teniposide for 48 h and the cell growth was inhibited by 50% at 48 nM.
Name Type Language
TENIPOSIDE
HSDB   INN   MART.   MI   ORANGE BOOK   USAN   USP-RS   VANDF   WHO-DD  
USAN   INN  
Official Name English
TENIPOSIDE [USP MONOGRAPH]
Common Name English
teniposide [INN]
Common Name English
TENIPOSIDE [VANDF]
Common Name English
4'-DEMETHYLEPIPODOPHYLLOTOXIN 9-(4,6-O-(R)-2-THENYLIDENE-.BETA.-D-GLUCOPYRANOSIDE)
Common Name English
TENIPOSIDE [ORANGE BOOK]
Common Name English
VUMON
Brand Name English
Teniposide [WHO-DD]
Common Name English
TENIPOSIDE [USP-RS]
Common Name English
TENIPOSIDE [IARC]
Common Name English
TENIPOSIDE [MI]
Common Name English
NSC-122819
Code English
FURO(3',4':6,7)NAPHTHO(2,3-D)-1,3-DIOXOL-6(5AH)-ONE, 5,8,8A,9-TETRAHYDRO-5-(4-HYDROXY-3,5-DIMETHOXYPHENYL)-9-((4,6-O-(2-THIENYLMETHYLENE)-.BETA.-D-GLUCOPYRANOSYL)-OXY)-, (5R-(5.ALPHA.,5A.BETA.,8A.ALPHA.,9.BETA.(R*)))
Common Name English
TENIPOSIDE [MART.]
Common Name English
VM26
Code English
TENIPOSIDE [HSDB]
Common Name English
VM-26
Code English
TENIPOSIDE [USAN]
Common Name English
Classification Tree Code System Code
NDF-RT N0000000176
Created by admin on Sat Dec 16 16:16:06 GMT 2023 , Edited by admin on Sat Dec 16 16:16:06 GMT 2023
FDA ORPHAN DRUG 883
Created by admin on Sat Dec 16 16:16:06 GMT 2023 , Edited by admin on Sat Dec 16 16:16:06 GMT 2023
WHO-ATC L01CB02
Created by admin on Sat Dec 16 16:16:06 GMT 2023 , Edited by admin on Sat Dec 16 16:16:06 GMT 2023
WHO-VATC QL01CB02
Created by admin on Sat Dec 16 16:16:06 GMT 2023 , Edited by admin on Sat Dec 16 16:16:06 GMT 2023
LIVERTOX NBK548102
Created by admin on Sat Dec 16 16:16:06 GMT 2023 , Edited by admin on Sat Dec 16 16:16:06 GMT 2023
NDF-RT N0000175609
Created by admin on Sat Dec 16 16:16:06 GMT 2023 , Edited by admin on Sat Dec 16 16:16:06 GMT 2023
NCI_THESAURUS C1331
Created by admin on Sat Dec 16 16:16:06 GMT 2023 , Edited by admin on Sat Dec 16 16:16:06 GMT 2023
Code System Code Type Description
MERCK INDEX
m10558
Created by admin on Sat Dec 16 16:16:06 GMT 2023 , Edited by admin on Sat Dec 16 16:16:06 GMT 2023
PRIMARY Merck Index
RXCUI
10362
Created by admin on Sat Dec 16 16:16:06 GMT 2023 , Edited by admin on Sat Dec 16 16:16:06 GMT 2023
PRIMARY RxNorm
NSC
122819
Created by admin on Sat Dec 16 16:16:06 GMT 2023 , Edited by admin on Sat Dec 16 16:16:06 GMT 2023
PRIMARY
SMS_ID
100000082949
Created by admin on Sat Dec 16 16:16:06 GMT 2023 , Edited by admin on Sat Dec 16 16:16:06 GMT 2023
PRIMARY
CHEBI
75988
Created by admin on Sat Dec 16 16:16:06 GMT 2023 , Edited by admin on Sat Dec 16 16:16:06 GMT 2023
PRIMARY
ChEMBL
CHEMBL452231
Created by admin on Sat Dec 16 16:16:06 GMT 2023 , Edited by admin on Sat Dec 16 16:16:06 GMT 2023
PRIMARY
PUBCHEM
452548
Created by admin on Sat Dec 16 16:16:06 GMT 2023 , Edited by admin on Sat Dec 16 16:16:06 GMT 2023
PRIMARY
RS_ITEM_NUM
1643736
Created by admin on Sat Dec 16 16:16:06 GMT 2023 , Edited by admin on Sat Dec 16 16:16:06 GMT 2023
PRIMARY
NCI_THESAURUS
C857
Created by admin on Sat Dec 16 16:16:06 GMT 2023 , Edited by admin on Sat Dec 16 16:16:06 GMT 2023
PRIMARY
EPA CompTox
DTXSID8023638
Created by admin on Sat Dec 16 16:16:06 GMT 2023 , Edited by admin on Sat Dec 16 16:16:06 GMT 2023
PRIMARY
HSDB
6546
Created by admin on Sat Dec 16 16:16:06 GMT 2023 , Edited by admin on Sat Dec 16 16:16:06 GMT 2023
PRIMARY
DRUG CENTRAL
2590
Created by admin on Sat Dec 16 16:16:06 GMT 2023 , Edited by admin on Sat Dec 16 16:16:06 GMT 2023
PRIMARY
IUPHAR
6843
Created by admin on Sat Dec 16 16:16:06 GMT 2023 , Edited by admin on Sat Dec 16 16:16:06 GMT 2023
PRIMARY
FDA UNII
957E6438QA
Created by admin on Sat Dec 16 16:16:06 GMT 2023 , Edited by admin on Sat Dec 16 16:16:06 GMT 2023
PRIMARY
MESH
D013713
Created by admin on Sat Dec 16 16:16:06 GMT 2023 , Edited by admin on Sat Dec 16 16:16:06 GMT 2023
PRIMARY
ECHA (EC/EINECS)
249-831-2
Created by admin on Sat Dec 16 16:16:06 GMT 2023 , Edited by admin on Sat Dec 16 16:16:06 GMT 2023
PRIMARY
DRUG BANK
DB00444
Created by admin on Sat Dec 16 16:16:06 GMT 2023 , Edited by admin on Sat Dec 16 16:16:06 GMT 2023
PRIMARY
EVMPD
SUB10895MIG
Created by admin on Sat Dec 16 16:16:06 GMT 2023 , Edited by admin on Sat Dec 16 16:16:06 GMT 2023
PRIMARY
WIKIPEDIA
TENIPOSIDE
Created by admin on Sat Dec 16 16:16:06 GMT 2023 , Edited by admin on Sat Dec 16 16:16:06 GMT 2023
PRIMARY
INN
3836
Created by admin on Sat Dec 16 16:16:06 GMT 2023 , Edited by admin on Sat Dec 16 16:16:06 GMT 2023
PRIMARY
CAS
29767-20-2
Created by admin on Sat Dec 16 16:16:06 GMT 2023 , Edited by admin on Sat Dec 16 16:16:06 GMT 2023
PRIMARY
ACTIVE MOIETY
Structure of TENIPOSIDE
METABOLITE (PARENT)
Structure of TENIPOSIDE CATECHOL
METABOLITE (PARENT)
Structure of TENIPOSIDE ORTHOQUINONE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966